1. Anti-infection
  2. HIV Reverse Transcriptase HBV
  3. Lamivudine

Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.

For research use only. We do not sell to patients.

Lamivudine Chemical Structure

Lamivudine Chemical Structure

CAS No. : 134678-17-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 113 In-stock
Solution
10 mM * 1 mL in DMSO USD 113 In-stock
Solid
100 mg USD 103 In-stock
500 mg USD 262 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Lamivudine:

Top Publications Citing Use of Products

View All HIV Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

Cellular Effect
Cell Line Type Value Description References
C8166 CC50
> 1000 μM
Compound: 3TC
Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Toxicity in human C8166 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31310115]
Caco-2 IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human Caco2 cells assessed as growth inhibition after 3 days by particle counting analysis
[PMID: 24177359]
CCRF-CEM CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay
[PMID: 33421915]
CCRF-CEM IC50
> 100 μM
Compound: 3TC, Epivir
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
[PMID: 21700368]
CCRF-CEM CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human CEM cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28688280]
CCRF-CEM CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human CEM cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28094179]
CCRF-CEM IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against thymidine kinase-deficient human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
[PMID: 24177359]
CCRF-CEM IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis
[PMID: 24177359]
CCRF-CEM EC50
0.099 μM
Compound: 5, 3TC
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
[PMID: 24177359]
CCRF-CEM EC50
0.18 μM
Compound: 5, 3TC
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
[PMID: 24177359]
CCRF-CEM IC50
50 μM
Compound: beta-L-oxathiolanecytosine(3TC)
Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis
Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis
10.1016/0960-894X(95)00343-R
CEM-SS ED50
0.36 μM
Compound: 3TC
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
[PMID: 15217281]
CEM-SS EC50
200 nM
Compound: 12, 3TC
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
[PMID: 22858097]
CHO IC50
54.2 μM
Compound: lamivudine
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
[PMID: 23812503]
COLO 320 IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human COLO320 cells assessed as growth inhibition after 3 days by particle counting analysis
[PMID: 24177359]
H9 CC50
> 200 μM
Compound: Lamivudine
Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay
Cytotoxicity against human H9 cells assessed as cell viability incubated for 7 days by MTT colorimetric assay
[PMID: 34245947]
H9 EC50
0.06 μM
Compound: 3TC, NSC-697911, (2R-cis)-lamivudine
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
[PMID: 11430019]
H9 EC50
0.06 μM
Compound: 3TC, NSC-697911, (2R-cis)-lamivudine
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
[PMID: 11430019]
HEK293 EC50
> 300 μM
Compound: Lamivudine
Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 CC50
≥ 25 μM
Compound: 3TC
Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay
Cytotoxicity against HEK293 cells assessed as cell viability by MTT assay
[PMID: 32678592]
HEK293 EC50
0.3 μM
Compound: 3TC
Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay
Antiviral activity against VSVG pseudotyped HIV1 infected in HEK293 cells preincubated for 3 hrs followed by compound washout and subsequent compound redosing and measured after 72 hrs by luciferase reporter gene based assay
[PMID: 32678592]
HEK293 EC50
3.25 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
3.54 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
3.9 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
4.06 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
4.24 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
4.48 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
4.68 μM
Compound: Lamivudine
Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
4.78 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
5.43 μM
Compound: Lamivudine
Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK293 EC50
7.16 μM
Compound: Lamivudine
Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs
[PMID: 20308377]
HEK-293T CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
[PMID: 17470654]
HEK-293T EC50
> 20000 nM
Compound: 3TC
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
[PMID: 22148316]
HeLa CC50
> 20 μM
Compound: Lamivudine
Cytotoxicity against mock-infected human HeLa cells by MTT assay
Cytotoxicity against mock-infected human HeLa cells by MTT assay
[PMID: 25682562]
HeLa IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against thymidine kinase-deficient human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
[PMID: 24177359]
HeLa IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis
[PMID: 24177359]
HeLa EC50
> 436 μM
Compound: 3TC, Lamivudine
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
[PMID: 22352809]
HeLa EC50
> 436.6 μM
Compound: 1, lamivudine, 3TC
Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay
Cytotoxicity against human HeLa P4/R5 cells incubated for 2 hrs followed by compound-wash out measured after 46 hrs by MTS assay
[PMID: 22533850]
HeLa EC50
11.3 μM
Compound: 3TC, Lamivudine
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
[PMID: 22352809]
HeLa EC50
11.4 μM
Compound: 1, lamivudine, 3TC
Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
Antiviral activity against HIV1 BaL assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
[PMID: 22533850]
HeLa EC50
32.7 μM
Compound: 1, lamivudine, 3TC
Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
Antiviral activity against HIV1 3B assessed as inhibition of infection in HeLa P4/R5 cells expressing CD4 receptor and beta-gal incubated for 2 hrs followed by compound-wash out measured after 46 hrs by single round infection MAGI assay
[PMID: 22533850]
HeLa EC50
32.7 μM
Compound: 3TC, Lamivudine
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
[PMID: 22352809]
Hepatocyte EC50
0.05 μg/mL
Compound: 3-TC, Lamivudine
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days
Antiviral activity against DHBV infected in duck hepatocytes assessed as inhibition of viral DNA replication after 2 days
[PMID: 20869253]
HepG2 IC50
> 1 μM
Compound: 3TC
Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay
Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay
[PMID: 17488817]
HepG2 CC50
> 10 μM
Compound: 3TC
Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
[PMID: 25849312]
HepG2 CC50
> 10 μM
Compound: 3TC
Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
[PMID: 25849312]
HepG2 IC50
> 10 μM
Compound: 3TC
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
[PMID: 28595015]
HepG2 IC50
> 10 μM
Compound: 3TC
Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
[PMID: 28595015]
HepG2 IC50
> 10 μM
Compound: 3TC
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
[PMID: 30653317]
HepG2 IC50
> 10 μM
Compound: 3TC
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
[PMID: 30653317]
HepG2 CC50
> 10 μM
Compound: 3TC
Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human HepG2 cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28688280]
HepG2 CC50
> 10 μM
Compound: 3TC
Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28094179]
HepG2 CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
[PMID: 33421915]
HepG2 EC50
> 2.5 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting
Antiviral activity against Hepatitis B virus infected in human HepG2 cells assessed as reduction in viral DNA after 3 days by Southern blotting
[PMID: 21333535]
HepG2 CC50
> 25 μM
Compound: 3TC
Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay
Cytotoxicity against human HepG2 cells after 3 days by neutral red dye uptake assay
[PMID: 21333535]
HepG2 CC50
> 500 μM
Compound: 3TC
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 3 days by MTT assay
[PMID: 35776695]
HepG2 EC50
0.038 μM
Compound: Lamivudine (3TC)
Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
10.1016/S0960-894X(97)00422-8
HepG2 EC50
0.4 μM
Compound: 3TC (2'-deoxy-3'thiacytidine)
In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV
In vitro concentration required to inhibit HBV DNA secretion by HepG2.2.15 transfected by HBV
[PMID: 12852943]
HepG2 CC50
100 μM
Compound: 3TC
Cytotoxicity against HBV transfected human HepG2 cells by MTT assay
Cytotoxicity against HBV transfected human HepG2 cells by MTT assay
[PMID: 17488817]
HepG2 CC50
1200 μM
Compound: 3TC, lamivudine
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
[PMID: 17404006]
HepG2 IC50
1792 μM
Compound: Lamivudine (3TC)
Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
10.1016/S0960-894X(97)00422-8
HepG2 2.2.15 CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 8 days by CCK-8 assay
[PMID: 28494252]
HepG2 2.2.15 CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as decrease in cell viability after 8 days by CCK-8 assay
[PMID: 27484509]
HepG2 2.2.15 CC50
> 100 μM
Compound: LAM
Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay
Cytotoxicity against human HepG2 2.2.15 cells infected with Hepatitis B virus assessed as reduction in cell growth by CCK8 assay
[PMID: 35123297]
HepG2 2.2.15 CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 4 days prior to compound washout followed by compound addition and measured after 4 days by CCK8 assay
[PMID: 32712535]
HepG2 2.2.15 CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 2.2.15 cell line assessed as cell viability measured after 72 hrs by MTT assay
[PMID: 33285406]
HepG2 2.2.15 CC50
> 100 μM
Compound: 3 TC
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32791397]
HepG2 2.2.15 CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability measured after 72 hrs by MTT assay
[PMID: 31091479]
HepG2 2.2.15 CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 29288943]
HepG2 2.2.15 CC50
> 100 μM
Compound: 3TC
Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay
Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay
[PMID: 17488817]
HepG2 2.2.15 EC50
> 100 μM
Compound: Lamivudine
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
[PMID: 21930377]
HepG2 2.2.15 EC50
> 100 μM
Compound: Lamivudine
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
[PMID: 21930377]
HepG2 2.2.15 EC50
> 100 μM
Compound: Lamivudine
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb
[PMID: 21930377]
HepG2 2.2.15 EC50
> 100 μM
Compound: 3TC
Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
[PMID: 20117930]
HepG2 2.2.15 EC50
> 100 μM
Compound: 3TC
Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
[PMID: 20117930]
HepG2 2.2.15 EC50
> 100 μM
Compound: 3TC
Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
[PMID: 20117930]
HepG2 2.2.15 IC50
> 1000 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA
[PMID: 23369536]
HepG2 2.2.15 CC50
> 1000 μM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay
[PMID: 23369536]
HepG2 2.2.15 CC50
> 1000 μM
Compound: lamivudine
Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay
Cytotoxicity against HepG2.2.15 cells after 6 hrs by MTT assay
[PMID: 17499889]
HepG2 2.2.15 CC50
> 1000 μM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells after 9 days by MTT assay
[PMID: 29174810]
HepG2 2.2.15 CC50
> 2 μM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 1 to 4 hrs by MTS uptake assay
[PMID: 35754374]
HepG2 2.2.15 CC50
> 2 μM
Compound: 3TC
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability by MTS assay
[PMID: 27748590]
HepG2 2.2.15 CC50
> 2 μM
Compound: Lamivudine
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay
[PMID: 28682067]
HepG2 2.2.15 CC50
> 20 μM
Compound: LAM
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human HepG2 2.2.15 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 36228413]
HepG2 2.2.15 IC50
> 2000 μM
Compound: 3TC
Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs
Cytotoxicity against human HepG2(2.2.15) cells assessed as uptake of neutral red dye after 24 hrs
[PMID: 19072694]
HepG2 2.2.15 EC50
> 500 μM
Compound: Lamivudine
Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h
Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h
[PMID: 21930377]
HepG2 2.2.15 EC50
0.0038 μM
Compound: 3TC
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis
[PMID: 32421339]
HepG2 2.2.15 EC50
0.02 μM
Compound: lamivudine
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
[PMID: 17004726]
HepG2 2.2.15 EC50
0.02 μM
Compound: lamivudine
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
Inhibition of HBV replication in 2.2.15 cells by DNA hybridization assay
[PMID: 15615545]
HepG2 2.2.15 IC50
0.039 μM
Compound: lamivudine
Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay
Antiviral activity against HBV infected in human HepG22.2.15 cells after 3 days by neutral red dye-based plaque reduction assay
[PMID: 26260336]
HepG2 2.2.15 EC50
0.048 μM
Compound: 3TC
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as extracellular HBV virion DNA level after 24 hrs
[PMID: 19072694]
HepG2 2.2.15 EC50
0.06 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction in viral DNA by Southern blotting
[PMID: 21333535]
HepG2 2.2.15 EC50
0.1 μM
Compound: 3TC, lamivudine
Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR
Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR
[PMID: 17404006]
HepG2 2.2.15 EC50
0.15 μM
Compound: 3TC
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as replication intermediates after 24 hrs
[PMID: 19072694]
HepG2 2.2.15 IC50
0.16 μM
Compound: Lamivudine
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis after 8 days by RT-PCR analysis
[PMID: 20639110]
HepG2 2.2.15 EC50
0.2 μg/mL
Compound: 3-TC, Lamivudine
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 2 days
[PMID: 20869253]
HepG2 2.2.15 EC50
0.2 μM
Compound: Lamivudine
Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method
Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method
[PMID: 21930377]
HepG2 2.2.15 EC50
0.2 μM
Compound: Lamivudine
Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth
Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth
[PMID: 21930377]
HepG2 2.2.15 EC50
0.2 μM
Compound: 3TC
Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
[PMID: 20117930]
HepG2 2.2.15 EC50
0.2 μM
Compound: 3TC
Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
[PMID: 20117930]
HepG2 2.2.15 IC50
0.33 μM
Compound: lamivudine
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 4 days by RT-PCR analysis
[PMID: 21524588]
HepG2 2.2.15 EC50
1.5 μM
Compound: Lamivudine
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me
[PMID: 21930377]
HepG2 2.2.15 CC50
1020 μM
Compound: Lamivudine
Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay
Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay
[PMID: 28082068]
HepG2 2.2.15 IC50
11.7 mM
Compound: 3TC
Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA
Antiviral activity against HBV assessed as inhibition of viral surface antigen secretion in HepG2.2.15 cells by ELISA
[PMID: 18396905]
HepG2 2.2.15 CC50
1174 μM
Compound: lamivudine
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
[PMID: 21524588]
HepG2 2.2.15 IC50
14.8 μg/mL
Compound: Lamivudine
Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay
Antiviral activity against HBV infected in HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 8 days by radio immunoassay
[PMID: 20149495]
HepG2 2.2.15 IC50
141.32 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA
[PMID: 23434030]
HepG2 2.2.15 IC50
175.93 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA
[PMID: 23434030]
HepG2 2.2.15 CC50
2124 μM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability by neutral red uptake assay
[PMID: 35754374]
HepG2 2.2.15 CC50
2128 μM
Compound: 3TC
Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay
Cytotoxicity against human HepG2(2.2.15) cells by neutral red dye uptake assay
[PMID: 21333535]
HepG2 2.2.15 CC50
2183.1 μM
Compound: lamivudine
Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining
Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye staining
[PMID: 19457674]
HepG2 2.2.15 CC50
2183.1 μM
Compound: Lamivudine
Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method
Cytotoxicity against human HepG2(2.2.15) after 9 days by neutral dye uptake method
[PMID: 21074429]
HepG2 2.2.15 IC50
234.7 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA
[PMID: 25847765]
HepG2 2.2.15 IC50
240 μM
Compound: Lamivudine
Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis
Antiviral activity against Hepatitis B virus infected in HepG2.2.15 assessed as inhibition of HBV replication by quantitative Southern blot hybridization analysis
[PMID: 21074429]
HepG2 2.2.15 CC50
2400 μM
Compound: lamivudine
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
[PMID: 21401115]
HepG2 2.2.15 IC50
25.9 mM
Compound: 3TC
Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA
Antiviral activity against HBV assessed as inhibition of viral e-antigen secretion in HepG2.2.15 cells by ELISA
[PMID: 18396905]
HepG2 2.2.15 IC50
25.94 mM
Compound: 3TC
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBsAg antigen secretion after 72 hrs by ELISA
[PMID: 21823575]
HepG2 2.2.15 IC50
267.16 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA
[PMID: 25847765]
HepG2 2.2.15 IC50
27 mM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion after 6 days by ELISA
[PMID: 21145140]
HepG2 2.2.15 IC50
30 mM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion after 6 days by ELISA
[PMID: 21145140]
HepG2 2.2.15 CC50
30 mM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells by MTT assay
Cytotoxicity against human HepG2.2.15 cells by MTT assay
[PMID: 18396905]
HepG2 2.2.15 IC50
30.26 mM
Compound: 3TC
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as reduction in HBeAg antigen secretion after 72 hrs by ELISA
[PMID: 21823575]
HepG2 2.2.15 CC50
33.25 mM
Compound: 3TC
Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay
Cytotoxicity in human HepG2(2.2.15) cells after 72 hrs by MTT assay
[PMID: 21823575]
HepG2 2.2.15 CC50
391.21 μM
Compound: 3TC
Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay
[PMID: 23434030]
HepG2 2.2.15 IC50
4.51 μg/mL
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by semi-quantitative EIA
[PMID: 21183354]
HepG2 2.2.15 IC50
405.6 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA
[PMID: 23369536]
HepG2 2.2.15 IC50
49.13 μg/mL
Compound: 3TC
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of surface antigen secretion by EIA
[PMID: 25600408]
HepG2 2.2.15 CC50
5 μM
Compound: Lamivudine
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay
[PMID: 20639110]
HepG2 2.2.15 EC50
5.3 μM
Compound: 3TC
Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization
[PMID: 20117930]
HepG2 2.2.15 CC50
568.25 μM
Compound: 3TC
Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay
[PMID: 25847765]
HepG2 2.2.15 IC50
58 μM
Compound: lamivudine
Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA
Antiviral activity against HBV transfected in human HepG2(2.2.15) cells assessed as inhibition of HBsAg secretion by ELISA
[PMID: 21401115]
HepG2 2.2.15 IC50
6.86 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis
[PMID: 25847765]
HepG2 2.2.15 IC50
7.63 μM
Compound: 3TC
Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis
Decrease in HBV viral DNA replication in human HepG2(2.2.15) cells at 0.75 to 3 uM after 72 hrs by real-time PCR analysis
[PMID: 25461891]
HepG2 2.2.15 IC50
82.42 μM
Compound: Lamivudine
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by measuring HBsAg and HBeAg production after 9 days by EIA
[PMID: 21872478]
HepG2 2.2.15 IC50
82.42 μM
Compound: Lamivudine
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization
Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral genome replication after 9 days by Southern blot hybridization
[PMID: 19307124]
HepG2 2.2.15 IC50
99.45 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis
[PMID: 23434030]
HL-60 CC50
1400 μM
Compound: 3TC, lamivudine
Cytotoxicity against human HL60 cells after 3 days by MTT assay
Cytotoxicity against human HL60 cells after 3 days by MTT assay
[PMID: 17404006]
Huh-7 EC50
> 100 μM
Compound: Lamivudine
Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
[PMID: 19398648]
Huh-7 EC50
> 100 μM
Compound: Lamivudine
Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
[PMID: 19398648]
Huh-7 EC50
> 100 μM
Compound: Lamivudine
Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
[PMID: 19398648]
Huh-7 EC50
> 100 μM
Compound: 3TC
Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
> 100 μM
Compound: 3TC
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
> 100 μM
Compound: 3TC
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
0.03 μM
Compound: LMV
Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBV genotype D with reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
[PMID: 17438047]
Huh-7 EC50
0.03 μM
Compound: LMV
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation and reverse transcriptase L80I mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
[PMID: 17438047]
Huh-7 CC50
0.1 μM
Compound: 3TC
Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay
Cytotoxicity against human HuH7 cells after 4 days by neutral red dye uptake assay
[PMID: 21333535]
Huh-7 EC50
0.1 μM
Compound: 3TC
Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting
Antiviral activity against Hepatitis B virus infected in human Huh7 cells assessed as reduction in viral DNA after 1 day by Southern blotting
[PMID: 21333535]
Huh-7 EC50
0.2 μM
Compound: Lamivudine
Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
[PMID: 19398648]
Huh-7 EC50
0.2 μM
Compound: 3TC
Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
0.3 μM
Compound: Lamivudine
Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
[PMID: 19398648]
Huh-7 EC50
0.3 μM
Compound: 3TC
Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
0.41 μM
Compound: LMV
Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBV genotype D in human Huh7 cells assessed as inhibition of viral replication after 5 days
[PMID: 17438047]
Huh-7 EC50
0.46 μM
Compound: LMV
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
Antiviral activity against HBeAg-deficient HBV genotype D with precore G1896A mutation in human Huh7 cells assessed as inhibition of viral replication after 5 days
[PMID: 17438047]
Huh-7 EC50
1.3 μM
Compound: 3TC
Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant wild type HBV in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
1.5 μM
Compound: 3TC
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204V mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
1.6 μM
Compound: 3TC
Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
1.6 μM
Compound: 3TC
Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase LM/reverse transcriptase MV double mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
1.8 μM
Compound: 3TC
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase M204I mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
10 μM
Compound: 3TC
Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against lamivudine-resistant HBV reverse transcriptase L180M mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
Huh-7 EC50
16 μM
Compound: Lamivudine
Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs
[PMID: 19398648]
Huh-7 EC50
7.7 μM
Compound: 3TC
Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
Antiviral activity against adefovir-resistant HBV reverse transcriptase 236T mutant in human Huh7 cells after 4 days by intracellular HBV DNA replication assay
[PMID: 19072694]
L1210 IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
Cytostatic activity against thymidine kinase-deficient mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
[PMID: 24177359]
L1210 IC50
> 250 μM
Compound: 5, 3TC
Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis
[PMID: 24177359]
MOLT-3 CC50
5.94 μg/mL
Compound: 3TC
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
[PMID: 21334901]
MOLT-4 EC50
> 100 μM
Compound: LVD
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
[PMID: 18316521]
MT2 EC50
0.04 μM
Compound: LVD
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.047 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.063 μM
Compound: LVD
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.086 μM
Compound: LVD
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.105 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.171 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.182 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.183 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.202 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
[PMID: 18316521]
MT2 EC50
0.219 μM
Compound: LVD
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.372 μM
Compound: LVD
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.462 μM
Compound: LVD
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.554 μM
Compound: LVD
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.667 μM
Compound: LVD
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
0.8 μM
Compound: Lamivudine
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
[PMID: 21115794]
MT2 EC50
0.8 μM
Compound: Lamivudine
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
[PMID: 21115794]
MT2 EC50
0.8 μM
Compound: Lamivudine
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysis
[PMID: 21115794]
MT2 EC50
0.8 μM
Compound: Lamivudine
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi
Antiviral activity against Human immunodeficiency virus 1 3B harboring reverse transcriptase M184V, M184I, K82N mutant infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected on day 14 after 4 passages by PCR analysi
[PMID: 21115794]
MT2 EC50
0.927 μM
Compound: LVD
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
0.969 μM
Compound: LVD
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
1.14 μM
Compound: LVD
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
[PMID: 18316521]
MT2 EC50
1.259 μM
Compound: LVD
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
1.683 μM
Compound: LVD
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
1.985 μM
Compound: LVD
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
2.445 μM
Compound: LVD
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT2 EC50
2.47 μM
Compound: LVD
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
[PMID: 18316521]
MT2 EC50
3.247 μM
Compound: LVD
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
[PMID: 18316521]
MT4 CC50
> 20 μM
Compound: 3 TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
[PMID: 34583311]
MT4 CC50
> 42 μM
Compound: 3TC
Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay
Cytotoxicity in human MT4 cells expressing GFP assessed as reduction in cell viability incubated for 48 hrs by cell-titer-Glo luminescent cell viability assay
[PMID: 30265808]
MT4 CC50
> 7.5 μM
Compound: Lamivudine
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
[PMID: 31767136]
MT4 CC50
> 87 μM
Compound: lamivudine
Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay
[PMID: 25946116]
MT4 CC50
> 87 μM
Compound: 3 TC
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
[PMID: 25707013]
MT4 CC50
> 87 μM
Compound: 3 TC
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
[PMID: 25626145]
MT4 CC50
> 87 μM
Compound: lamivudine
Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay
[PMID: 24926807]
MT4 CC50
> 87 μM
Compound: 3TC
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
[PMID: 24119448]
MT4 CC50
> 87.2 μM
Compound: 3TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
[PMID: 32977301]
MT4 CC50
> 87.2 μM
Compound: 3TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 30721060]
MT4 CC50
> 87.2 μM
Compound: 3TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28659246]
MT4 CC50
> 87.2 μM
Compound: 3TC
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
[PMID: 27748590]
MT4 CC50
> 87.2 μM
Compound: 3TC
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 27267005]
MT4 CC50
> 87.2 μM
Compound: 3TC
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
[PMID: 24794751]
MT4 CC50
> 87.24 μM
Compound: 3 TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
[PMID: 31434039]
MT4 CC50
> 87.24 μM
Compound: 3 TC
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
[PMID: 25240095]
MT4 CC50
> 87.24 μM
Compound: Lamivudine
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
[PMID: 24952305]
MT4 CC50
> 87.24 μM
Compound: 3TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
[PMID: 35754374]
MT4 CC50
> 87.24 μM
Compound: 3TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
[PMID: 33279288]
MT4 CC50
> 87.24 μM
Compound: 3TC
Cytotoxicity against human MT4 cells after 5 days MTT assay
Cytotoxicity against human MT4 cells after 5 days MTT assay
[PMID: 25537532]
MT4 CC50
> 87.3 μM
Compound: 3 TC
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
[PMID: 35780636]
MT4 CC50
> 87.3 μM
Compound: 3TC
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 30606670]
MT4 CC50
> 87240 nM
Compound: 3TC
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 27541578]
MT4 CC50
> 87240 nM
Compound: 3TC
Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
[PMID: 34890994]
MT4 IC50
0.1 μM
Compound: 1
Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells
Concentration required to inhibit syntica formation by 50% in HIV-1 infected MT-4 cells
[PMID: 8035429]
MT4 IC50
0.58 μg/mL
Compound: Lamivudine
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay
[PMID: 27105027]
MT4 EC50
0.89 μM
Compound: Lamivudine
Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
[PMID: 25682562]
MT4 EC50
1.8 μM
Compound: 3TC
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
[PMID: 24119448]
MT4 IC50
15.5 μM
Compound: lamivudine
Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
[PMID: 24926807]
MT4 EC50
15.5 μM
Compound: lamivudine
Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
[PMID: 25946116]
MT4 IC50
15.53 μM
Compound: Lamivudine
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
[PMID: 24952305]
MT4 EC50
2.2 μM
Compound: 3 TC
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 25707013]
MT4 EC50
2.22 μM
Compound: 3TC
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 27748590]
MT4 EC50
2.22 μM
Compound: 3 TC
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
[PMID: 25240095]
MT4 EC50
2.24 μM
Compound: 3TC
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 25537532]
MT4 EC50
2.442 μM
Compound: 3TC
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
[PMID: 24794751]
MT4 CC50
20 μg/mL
Compound: Lamivudine
Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay
Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay
[PMID: 27105027]
MT4 EC50
2239 nM
Compound: 3 TC
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 25626145]
MT4 EC50
2240 nM
Compound: 3TC
Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
[PMID: 27541578]
MT4 EC50
3.1 μM
Compound: 3TC
Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 27267005]
MT4 EC50
3.56 μM
Compound: Lamivudine
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
[PMID: 25682562]
MT4 IC50
3.89 μM
Compound: Lamivudine
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
[PMID: 24952305]
MT4 IC50
3.9 μM
Compound: lamivudine
Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay
[PMID: 24926807]
MT4 EC50
3.9 μM
Compound: lamivudine
Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay
[PMID: 25946116]
MT4 EC50
5.9 μM
Compound: 3TC
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
[PMID: 24119448]
MT4 EC50
7.2 μM
Compound: 3TC
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
[PMID: 24794751]
MT4 EC50
8.79 μM
Compound: 3TC
Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 25537532]
MT4 EC50
8.81 μM
Compound: 3TC
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
[PMID: 27748590]
MT4 EC50
8.81 μM
Compound: 3 TC
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
[PMID: 25240095]
MT4 EC50
8790 nM
Compound: 3TC
Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
[PMID: 27541578]
PBMC CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay
[PMID: 33421915]
PBMC IC50
> 100 μM
Compound: 3TC, Epivir
Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay
[PMID: 21700368]
PBMC CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human PBMC by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28688280]
PBMC CC50
> 100 μM
Compound: 3TC
Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against human PBMC assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28094179]
PBMC CC50
> 13097 nM
Compound: 1, lamivudine, 3TC
Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days
Cytotoxicity against PHA-stimulated human PBMC incubated for 6 hrs followed by compound-wash out measured after 6 days
[PMID: 22533850]
PBMC EC50
0.04 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
[PMID: 18316521]
PBMC EC50
0.071 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
[PMID: 18316521]
PBMC EC50
0.081 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
[PMID: 18316521]
PBMC EC50
0.85 μM
Compound: LVD
Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
[PMID: 18316521]
PBMC CC50
52.97 μg/mL
Compound: 3TC
Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay
Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay
[PMID: 21334901]
Vero CC50
> 100 μg/mL
Compound: 3-TC(Lamivudine)
Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay
Cytotoxic concentration required to reduce the viability of Vero cells as determined by MTT assay
[PMID: 11985471]
Vero CC50
> 100 μg/mL
Compound: 1a (Lamivudine)
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay
[PMID: 11677126]
Vero CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
[PMID: 33421915]
Vero IC50
> 100 μM
Compound: 3TC, Epivir
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry
[PMID: 21700368]
Vero CC50
> 100 μM
Compound: 3TC
Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against African green monkey Vero cells by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28688280]
Vero CC50
> 100 μM
Compound: 3TC
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CellTiter 96 non-radioactive cell proliferation colorimetric assay
[PMID: 28094179]
WI-38 CC50
> 100 μM
Compound: Lamivudine
Cytotoxicity against human WI38 cells by neutral red assay
Cytotoxicity against human WI38 cells by neutral red assay
[PMID: 18285481]
WI-38 EC50
> 100 μM
Compound: Lamivudine
Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis
[PMID: 18285481]
In Vitro

Lamivudine (1 μM) is potent inhibitor of hepatitis B virus (HBV) replication, shows antiviral activity in primary duck hepatocyte (PDH) cultures derived from ducklings congenitally infected with the duck hepatitis B virus (DHBV)[1].
Lamivudine (0-20 μM; 2, 4, 9 d) inhibits DHBV replication with 50% inhibitory concentration of 0.55 μM[1].
Lamivudine, combinded with penciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine [PCV]), (1 μM; 2, 4, 9 d) shows synergistic effect, acts potent function in reducing the normally recalcitrant viral covalently closed circular (CCC) DNA form of DHBV[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lamivudine (20-500 mg/kg/d; p.o.; 15 or 45 d) causes oxidative stress and is toxic to rat liver[2].
Lamivudine (50 mg/kg; i.p.; single dose) penetrates well in CNS and localizes in brain regions susceptible to HIV neurodegeneration in rat[3].
Pharmacokinetic Parameters of Lamivudine in HIV-infected Rats[3]

Parameter Cmax (μg/mL) Tmax (h) T1/2 (h) AUC (h·ng/mL)
Plasma 25,846 0.25 0.68 22,172
Brain 272 0.5 1.2 967
Pharmacokinetic data measured over a 24-h period, sampling was done at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, and 24.0 h postdose.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar female rats[2]
Dosage: 20-500 mg/kg/day
Administration: Oral gavage; single or repeated dose; 15 or 45 days
Result: Increased activities of the aminotransferases (ALT and AST), γ-glutamyltransferase (GGT) and total protein concentration in serum at 500 mg/kg dose.
Increased activities of glutathione S-transferase (GST), GGT and superoxide dismutase (SOD) as well as concentrations of malondialdehyde (MDA) and protein at 20 mg/kg dose.
Caused multifocal lymphocyte population and hepatocyte edema degeneration in hepatic sinusoids of chickens.
Clinical Trial
Molecular Weight

229.26

Formula

C8H11N3O3S

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC[C@H]1SC[C@@H](N2C(N=C(N)C=C2)=O)O1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (218.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 50 mg/mL (218.09 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.3618 mL 21.8092 mL 43.6184 mL
5 mM 0.8724 mL 4.3618 mL 8.7237 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (10.90 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (10.90 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (436.18 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.97%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 4.3618 mL 21.8092 mL 43.6184 mL 109.0460 mL
5 mM 0.8724 mL 4.3618 mL 8.7237 mL 21.8092 mL
10 mM 0.4362 mL 2.1809 mL 4.3618 mL 10.9046 mL
15 mM 0.2908 mL 1.4539 mL 2.9079 mL 7.2697 mL
20 mM 0.2181 mL 1.0905 mL 2.1809 mL 5.4523 mL
25 mM 0.1745 mL 0.8724 mL 1.7447 mL 4.3618 mL
30 mM 0.1454 mL 0.7270 mL 1.4539 mL 3.6349 mL
40 mM 0.1090 mL 0.5452 mL 1.0905 mL 2.7262 mL
50 mM 0.0872 mL 0.4362 mL 0.8724 mL 2.1809 mL
60 mM 0.0727 mL 0.3635 mL 0.7270 mL 1.8174 mL
80 mM 0.0545 mL 0.2726 mL 0.5452 mL 1.3631 mL
100 mM 0.0436 mL 0.2181 mL 0.4362 mL 1.0905 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lamivudine
Cat. No.:
HY-B0250
Quantity:
MCE Japan Authorized Agent: